Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1228-1234

  Devillier, Raynier ^a   Crocchiolo, Roberto ^a   Etienne, Anne ^a   Prebet, Thomas ^a   Charbonnier, Aude ^a   Fürst, Sabine ^a   El Cheikh, Jean ^a   D'Incan, Evelyne ^a   Rey, Jérôme ^a   Faucher, Catherine ^a   Blaise, Didier ^a   Vey, Norbert ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Relapse

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; GEMTUZUMAB; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL EFFECTIVENESS; DONOR LYMPHOCYTE INFUSION; HUMAN; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877738624     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.741230     Document Type: Article

References (26)

1. Keating S, de Witte T, Suciu S, et al . The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: An analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto . Br J Haematol 1998; 102: 1344- 1353.
2. Zittoun RA, Mandelli F, Willemze R, et al . Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell ' Adulto (GIMEMA) Leukemia Cooperative Groups . N Engl J Med 1995; 332: 217- 223.
3. Ringden O, Labopin M, Ehninger G, et al . Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27 : 4570 - 4577.
4. F rassoni F, B arrett A J, G ranena A, et a l. R elapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases . Br J Haematol 1988; 70 : 317 - 320.
5. Mortimer J, Blinder MA, Schulman S, et al . Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50- 57.
6. Arellano ML, Langston A, Winton E, et al . Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience . Biol Blood Marrow Transplant 2007; 13 : 116 - 123.
7. Vardiman JW, Th iele J, Arber DA, et al . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes . Blood 2009; 114 : 937 - 951.
8. Dohner H, Estey EH, Amadori S, et al . Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115 : 453 - 474.
9. Prebet T, Etienne A, Devillier R, et al . Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in fi rst relapse with gemtuzumab and cytarabine versus cytarabine: Results of a retrospective comparative study . Cancer 2011; 117 : 974 - 981.
10. Cheson BD, Bennett JM, Kopecky KJ, et al . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21 : 4642 - 4649.
11. K aplan E L, M eier P. N onparametric estimation from incomplete observations . J Am Stat Assoc 1958; 53 : 457 - 481.
12. C ox D R. R egression models and life tables. J R Stat Soc B 1972; 3 4: 187 - 220.
13. Chevallier P, Delaunay J, Turlure P, et al . Long-term diseasefree survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33 (-) primary resistant or relapsed acute myeloid leukemia . J Clin Oncol 2008; 26 : 5192 - 5197.
14. Giles F, Vey N, DeAngelo D, et al . Phase 3 randomized, placebocontrolled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in fi rst relapse . Blood 2009; 114 : 4027 - 4033.
15. Vey N, Keating M, Giles F, et al . effect of complete remission on survival in patients with acute myelogenous leukemia receiving fi rst salvage therapy. Blood 1999; 93: 3149- 3150.
16. Oran B, Giralt S, Couriel D, et al . Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation . Leukemia 2007; 21 : 2540 - 2544.
17. Levine JE, Braun T, Penza SL, et al . Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation . J Clin Oncol 2002; 20 : 405 - 412.
18. S chmid C, L abopin M, N agler A, et a l. T reatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation . Blood 2012; 119 : 1599 - 1606.
19. Lee JH, Lee KH, Kim S, et al . Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation . Leuk Res 2001; 25 : 305 - 312.
20. Eapen M, Giralt SA, Horowitz MM, et al . Second transplant for acute and chronic leukemia relapsing after fi rst HLA-identical sibling transplant . Bone Marrow Transplant 2004; 34 : 721 - 727.
21. Bolanos-Meade J, Smith BD, Gore SD, et al . 5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. B iol Blood Marrow Transplant 2 011; 1 7: 7 54- 7 58.
22. Czibere A, Bruns I, Kroger N, et al . 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A retrospective analysis . Bone Marrow Transplant 2010; 45 : 872 - 876.
23. Jabbour E, Giralt S, Kantarjian H, et al . Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia . Cancer 2009; 115 : 1899 -1905
24. De Lima M, Giralt S, Th all PF, et al . Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule fi nding study. Cancer 2010; 116 : 5420 - 5431.
25. Bayraktar UD, Domingo GC, Schmit J, et al . Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia . Leuk Lymphoma 2011; 52 : 913 - 915.
26. Chowdhury S, Seropian S, Marks PW . Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia . Am J Hematol 2009; 84 : 599 - 600.